NAC

• Acetaminophen (paracetamol) overdose antidote (clinical pharmaceutical, first-line)
• Mucolytic for thick mucus in COPD, cystic fibrosis, and bronchitis (clinical)
• Schizophrenia adjunctive therapy (strongest supplement-side signal)
• Obsessive-compulsive disorder augmentation (mixed evidence)
• Substance-use craving reduction, notably cocaine and cannabis in younger users (preliminary)
• Polycystic ovary syndrome, insulin sensitivity and some reproductive measures
• General glutathione and antioxidant support (the common marketing rationale)

N-Acetylcysteine (NAC) is the N-acetylated form of the amino acid L-cysteine, an unusual molecule that occupies the boundary between pharmaceutical drug and dietary supplement and has remained there for sixty years. The acetylation modification serves two practical purposes: it improves oral bioavailability dramatically versus L-cysteine itself (which is poorly absorbed and unstable), and it provides chemical stability allowing both oral formulations and intravenous pharmaceutical preparations. The acetyl group is cleaved enzymatically in the liver and other tissues, liberating free cysteine that enters the body's cysteine pool. Cysteine in turn serves as the rate-limiting substrate for glutathione (GSH) biosynthesis, the body's most abundant intracellular antioxidant and the central reducing agent for numerous cellular processes (xenobiotic metabolism through GSH-S-transferases, peroxide detoxification through glutathione peroxidases, regeneration of vitamins C and E, sulfur amino acid metabolism). The glutathione-replenishment mechanism explains essentially all of NAC's therapeutic applications: in acetaminophen overdose, where massive acetaminophen metabolism through CYP2E1 produces the highly reactive N-acetyl-p-benzoquinone imine (NAPQI) that depletes hepatic glutathione and produces hepatotoxicity, NAC restores glutathione capacity and prevents or limits liver damage; in chronic respiratory disease, NAC supports glutathione status in airway epithelium while simultaneously providing direct mucolytic action through reduction of disulfide bonds in mucus glycoproteins; in psychiatric applications, NAC modulates glutamate signaling through cystine-glutamate antiporter (the Sxc- system) activity in addition to glutathione effects. The pharmacology spans extraordinary dose ranges. The acetaminophen overdose protocol uses 150mg/kg IV loading dose (approximately 10g for 70kg adult) followed by extended infusion, pharmaceutical pharmacology at concentrations that produce direct chemical effects. The chronic supplementation range (600-2400mg/day oral) supports glutathione status in healthy users and various clinical populations. The mucolytic mechanism through direct disulfide bond reduction is dose-related and substantial: NAC visibly thins mucus in cystic fibrosis sputum and chronic obstructive pulmonary disease secretions at therapeutic doses. The psychiatric mechanism involves cystine-glutamate antiporter activation that increases extracellular glutamate in nucleus accumbens, relevant to addiction circuits where NAC's preliminary efficacy in cocaine, gambling, and other addictive disorders has substantial mechanism support. The 2020-2022 FDA controversy emerged from this dual pharmacology, NAC's pharmaceutical history (approved IV preparations dating to 1963 in Italy, 1985 in the United States) under the strict reading of DSHEA could have disqualified it from supplement status. The FDA's November 2022 enforcement discretion announcement effectively restored the consumer supplement category, though the formal regulatory status remains technically ambiguous.

Standard NAC supplementation ranges from 600mg/day (general antioxidant support) to 2400-3000mg/day in divided doses (psychiatric and respiratory clinical applications). The typical consumer dose is 600-1200mg/day in 1-2 divided doses. Take with or between meals, absorption is acceptable either way but some users prefer between meals to avoid GI sensitivity. The sulfur smell can be unpleasant; effervescent forms or capsules taken with adequate water minimize this. The PCOS protocol typically uses 1800-2400mg/day in 2-3 divided doses for 12+ weeks. Psychiatric protocols (Bloch 2009 trichotillomania, Berk 2008 schizophrenia, Bloch OCD trials) use 2400mg/day in 2-3 divided doses with effects developing over 8-12 weeks. The acetaminophen overdose protocol is pharmaceutical pharmacology requiring emergency department coordination. The COPD evidence (BRONCUS 600mg twice daily) supports chronic respiratory dosing. NAC has substantial first-pass metabolism with relatively low oral bioavailability (~10% for unchanged NAC, but free cysteine bioavailability is higher), divided dosing improves cumulative plasma exposure. Effects vary by application: glutathione status improvements within days; psychiatric effects develop over 8-12 weeks; respiratory mucolytic effects within hours of inhaled or weeks for oral. The Upper Limit (UL) has not been formally established by IOM; chronic doses up to 3g/day are well-tolerated in clinical trials. Doses above 4g/day produce diminishing returns and increased GI side effects. The taste, smell, and sulfur-related body odor at high doses are the main practical limits on dosing.

General antioxidant support

600-1200mg/day

PCOS insulin sensitivity

1800-2400mg/day

OCD adjunctive (Sarris 2015)

2400-3000mg/day

Schizophrenia / bipolar adjunctive

2000mg/day

Trichotillomania (Bloch 2009)

2400mg/day

Cocaine dependence (Gray 2010)

1200-2400mg/day

COPD adjunctive (BRONCUS)

600mg twice daily

Acetaminophen overdose (IV)

150mg/kg loading + 50mg/kg + 100mg/kg infusion

• Standard Oral N-Acetylcysteine (NAC)

  Rating: gold

  The dominant consumer supplement form. Capsules typically 600-900mg per dose; effective and well-tolerated. NOW Foods, Thorne, Pure Encapsulations, Jarrow Formulas, Designs for Health all offer reliable products. Premium brands provide reasonable third-party testing. The 2020-2022 FDA controversy briefly disrupted US distribution but the category is now restored.

• NAC Effervescent (Pharmaceutical Grade)

  Rating: gold

  Pharmaceutical-grade effervescent NAC tablets dissolved in water, the form used in many European clinical protocols including the BRONCUS COPD trial. Faster absorption than capsule forms; substantially better-tolerated for the unpleasant sulfur taste. Mucinex Sinus-Max and similar OTC products include NAC effervescent forms.

• IV Acetadote (Pharmaceutical Acetaminophen Antidote)

  Rating: gold

  FDA-approved IV NAC for acetaminophen overdose treatment, 150mg/kg loading followed by extended infusion. Specialist administration in emergency departments and ICUs. The pharmaceutical pharmacology that established NAC's foundational evidence base; not a consumer supplement form.

• Nebulized NAC (Mucomyst)

  Rating: gold

  Inhaled NAC for cystic fibrosis and bronchiectasis mucus clearance. Direct mucolytic action through disulfide bond reduction in airway secretions. Pharmaceutical-grade; specialist respiratory medicine coordination. Can paradoxically cause bronchospasm in atopic asthma patients, usually pretreated with bronchodilator.

• NAC + Selenium / Glycine Combinations

  Rating: good

  Comprehensive glutathione support formulations combining NAC with selenium (cofactor for glutathione peroxidases), glycine (second glutathione precursor amino acid), and sometimes additional cofactors. Mechanistically reasonable for comprehensive antioxidant support; specific clinical superiority over standalone NAC at equivalent doses not definitively established.

• Liposomal Glutathione (Alternative to NAC)

  Rating: good

  Direct glutathione supplementation rather than precursor. Mechanistically distinct, glutathione absorption from oral products is debated; liposomal forms may provide modest absorption advantage. Premium pricing. Reasonable alternative for users seeking direct glutathione support; NAC remains more cost-effective and better-evidenced for most applications.

• Sustained-Release NAC

  Rating: good

  Extended-release formulations smoothing the NAC pharmacokinetic curve. Mechanistically reasonable for chronic dosing; clinical superiority over standard release at equivalent total dose not definitively established. Reasonable for users preferring once-daily dosing.

• NACET (N-Acetylcysteine Ethyl Ester)

  Rating: caution

  Experimental ester derivative with theoretical improved bioavailability and cell permeability. Limited clinical evidence; not widely available in commercial supplement market. Research-grade product; consumer use not warranted given limited safety and efficacy data.

• Acetaminophen overdose

  Strength of evidence for this group: strong

  THE foundational NAC indication. IV Acetadote protocol (150mg/kg loading + extended infusion) is standard antidote therapy globally with substantial mortality reduction in acetaminophen hepatotoxicity. Oral Prescott protocol remains alternative. Specialist emergency medicine coordination; this is not a consumer supplement use case but the foundational evidence that supports NAC's broader pharmacological credibility.

• Cystic fibrosis (mucolytic adjunct)

  Strength of evidence for this group: modest

  Inhaled NAC supports mucus clearance in CF respiratory disease. Oral high-dose NAC may modestly support overall pulmonary function. Standard of care has shifted substantially with CFTR modulators (Trikafta and others); NAC retains adjunctive role. Specialist CF clinic coordination.

• COPD (chronic obstructive pulmonary disease)

  Strength of evidence for this group: modest

  BRONCUS 2005 and subsequent trials show mixed evidence for NAC in COPD. Effect on lung function decline is minimal; modest reduction in exacerbations. Reasonable as adjunct to standard COPD therapy (bronchodilators, inhaled corticosteroids); not substitute for established treatment.

• OCD adjunctive (treatment-resistant)

  Strength of evidence for this group: modest

  Sarris 2015 systematic review and Afshar 2012, Mishra 2017, and other trials support NAC as adjunct to SSRIs in treatment-resistant OCD. Effect sizes modest but reasonable in established psychiatric practice. Psychiatry coordination for established OCD diagnosis.

• Trichotillomania and obsessive-compulsive spectrum

  Strength of evidence for this group: modest

  Bloch 2009 adult trichotillomania trial supports NAC at 2400mg/day. Subsequent work in skin picking (excoriation disorder) and related conditions has shown variable results. Psychiatry coordination; reasonable adjunct to standard behavioral therapy.

• Schizophrenia adjunctive (negative symptoms)

  Strength of evidence for this group: modest

  Berk 2008 and subsequent trials support NAC 2g/day as adjunct to standard antipsychotic for negative symptoms in chronic schizophrenia. Effect sizes modest; reasonable adjunct in established psychiatric practice. Coordinate with prescribing psychiatrist.

• Bipolar depression adjunctive

  Strength of evidence for this group: modest

  Berk 2008 supports NAC adjunctive to mood stabilizer for bipolar depressive episodes. Effect sizes modest; reasonable adjunct to standard mood stabilization. Coordinate with prescribing psychiatrist.

• Cocaine and other substance use disorders

  Strength of evidence for this group: modest

  Gray 2010 cocaine dependence and subsequent work in gambling (Grant 2008), nicotine, cannabis, and methamphetamine show variable preliminary evidence. Mechanism involves cystine-glutamate antiporter modulation in addiction circuits. Adjunct to established addiction treatment.

• Polycystic ovary syndrome (insulin sensitivity)

  Strength of evidence for this group: modest

  Multiple RCTs support NAC 1800-2400mg/day for insulin sensitivity, ovulation, and metabolic markers in PCOS. Effect sizes modest; reasonable adjunct to standard PCOS management.

• Fertility (male oxidative stress)

  Strength of evidence for this group: modest

  Multiple trials support NAC for sperm parameters in male infertility associated with oxidative stress. Effect sizes modest; reasonable adjunct to comprehensive fertility evaluation. Reproductive medicine coordination.

• NAFLD (non-alcoholic fatty liver disease)

  Strength of evidence for this group: cautious

  Preliminary evidence supports NAC in NAFLD insulin resistance and liver enzyme improvements. Specialist hepatology coordination; not established standalone NAFLD treatment.

• Healthy adults (glutathione status, general antioxidant)

  Strength of evidence for this group: cautious

  Reasonable component of comprehensive antioxidant nutrition for healthy adults. Effect sizes for hard endpoints in healthy users are modest. Glutathione status benefit is real; clinical relevance in non-deficient users debated. Reasonable adjunct, not foundational supplementation.

• COVID-19 and viral respiratory infections

  Strength of evidence for this group: cautious

  Some interest in NAC for COVID-19 based on antioxidant and mucolytic mechanisms; clinical evidence remains preliminary. Not supported as standalone COVID-19 treatment. Specialist coordination for severe respiratory illness.

• Pregnancy and lactation

  Strength of evidence for this group: cautious

  IV NAC is used clinically in pregnancy for acetaminophen overdose without recognized fetal harm. Routine supplementation at consumer doses lacks systematic pregnancy safety data; coordinate with OB-GYN for chronic supplementation in pregnancy.

• Glycine

  Interaction: synergy

  Glycine is the second amino acid precursor for glutathione synthesis (cysteine + glycine + glutamate → glutathione). Combined supplementation supports comprehensive glutathione synthesis. GlyNAC (glycine + NAC) protocols have substantial geriatric research interest.

• Selenium

  Interaction: synergy

  Selenium is cofactor for glutathione peroxidases, the enzymes that use glutathione to detoxify peroxides. NAC supports glutathione production; selenium supports glutathione utilization. Mechanistically complementary; common in comprehensive antioxidant protocols.

• Vitamin E

  Interaction: synergy

  Vitamin E intercepts lipid peroxyl radicals in cell membranes; glutathione (supported by NAC) regenerates oxidized vitamin E to active form. Mechanistically complementary antioxidant system.

• Vitamin C

  Interaction: synergy

  Both support antioxidant capacity through complementary mechanisms. Common combination in comprehensive antioxidant supplementation. The IV high-dose vitamin C + NAC combination is used in some integrative oncology protocols.

• Acetaminophen (Tylenol)

  Interaction: synergy

  The foundational NAC-drug interaction is therapeutic, NAC prevents acetaminophen hepatotoxicity through glutathione restoration. Routine combined use at typical doses is not recommended but emergency overdose treatment is established.

• Nitroglycerin

  Interaction: caution

  NAC enhances nitroglycerin vasodilatory effects through enhanced sulfhydryl group availability, can produce additive hypotension. Coordinate with cardiology for users on nitroglycerin therapy.

• Activated Charcoal

  Interaction: caution

  Activated charcoal can adsorb oral NAC reducing bioavailability, relevant in acetaminophen overdose where both may be used. Standard practice involves staggered administration or IV NAC.

• Anticoagulants and Antiplatelet Agents

  Interaction: caution

  Modest antiplatelet activity at high doses. Pre-surgical discontinuation 1-2 weeks before elective procedures is conservative practice; coordinate with prescribing physician for chronic anticoagulant users.

• Chemotherapy Agents

  Interaction: caution

  NAC may reduce effectiveness of certain chemotherapy agents through glutathione restoration in tumor cells. Particular concern with platinum-based agents (cisplatin, carboplatin) and alkylating agents. Coordinate with oncology; integrative oncology consensus generally recommends against routine NAC during active chemotherapy except where specifically indicated.

• Asthma Medications (Atopic Users)

  Interaction: caution

  Inhaled NAC can paradoxically cause bronchospasm in atopic asthma patients, usually pretreated with bronchodilator. Oral NAC is generally well-tolerated even in asthma. Specialist coordination for inhaled use.

Look for: clear N-Acetylcysteine designation (not just "cysteine"); explicit mg content per serving; appropriate dose for intended use (600-1200mg standard daily; higher for specific clinical applications); USP or NSF third-party verification; reputable manufacturer with quality control disclosure; reasonable price (NAC is genuinely inexpensive at supplement scale); consider effervescent or sustained-release formulations for high-dose or taste-sensitive applications. Avoid: very low-dose products (<300mg) for intended therapeutic use; proprietary "glutathione blends" obscuring NAC dose; products from manufacturers without third-party testing disclosure; aggressive marketing claims (cancer prevention, definitive psychiatric treatment) that exceed evidence base; very high single-dose products (>1200mg per serving) producing GI distress.

Research published from: Italy.

NAC's story begins in Italy at the pharmaceutical company Zambon in the early 1960s. Researchers seeking improved mucolytic agents identified N-acetylcysteine as a derivative of cysteine with substantial sulfhydryl-mediated activity against mucus glycoproteins, disulfide bond reduction visibly thinning thick secretions in respiratory disease. Zambon patented the compound and developed pharmaceutical formulations (Fluimucil oral, inhaled, and IV preparations) that became established mucolytic therapy in Italy and Europe by the late 1960s. The original Sheffner 1963 publication in Annals of the New York Academy of Sciences provided the foundational pharmacology characterization. The acetaminophen overdose therapeutic discovery came in 1973 from Mitchell and colleagues at the NIH, characterizing the glutathione depletion mechanism of acetaminophen hepatotoxicity through the reactive NAPQI intermediate. Prescott in Edinburgh tested NAC as glutathione precursor in acetaminophen overdose patients, publishing the foundational 1977 Lancet evidence of hepatotoxicity prevention. The Prescott 21-hour oral protocol became standard antidote therapy globally; Smilkstein's 1988 NEJM IV protocol validation extended treatment to patients unable to tolerate oral therapy. The FDA approval of IV Acetadote (Cumberland Pharmaceuticals) in 2004 completed the pharmaceutical regulatory pathway in the United States. The consumer supplement era developed substantially through the 1990s-2010s with NAC becoming widely available as glutathione precursor and antioxidant support. Multiple supplement manufacturers entered the US and European markets; quality and pricing stabilized at supplement-category levels. The respiratory disease evidence base expanded through trials in COPD (BRONCUS 2005), idiopathic pulmonary fibrosis (IFIGENIA 2005), and other respiratory conditions. The psychiatric era emerged through the 2000s-2010s. Olive Pharmaceuticals and academic researchers at the University of Pittsburgh characterized the cystine-glutamate antiporter mechanism in addiction circuits. Berk and colleagues at Deakin University in Australia conducted the foundational schizophrenia adjunctive trial (2008) and subsequent bipolar work. Bloch at Yale established the trichotillomania evidence base (2009); subsequent OCD spectrum work consolidated the psychiatric NAC framework. Sarris 2015 systematic review consolidated the OCD evidence; multiple subsequent trials have continued the psychiatric NAC research tradition. The COVID-19 era brought substantial new attention to NAC supplementation. Functional medicine guidance heavily emphasized NAC based on antioxidant mechanisms and theoretical respiratory benefits. Sales of NAC supplements increased substantially during 2020. The increased consumer attention prompted FDA examination of NAC's regulatory status, the agency issued warning letters in 2020-2021 arguing that NAC's pre-DSHEA pharmaceutical history (prior to 1994 DSHEA enactment) under strict reading disqualified it from supplement status. Amazon and other retailers briefly removed NAC products from US sales in 2021. Industry advocacy and consumer pressure produced FDA reconsideration; the November 2022 enforcement discretion announcement effectively restored the consumer supplement category. The formal regulatory status remains technically ambiguous, FDA has not issued formal rule-making to clarify NAC's permanent status under DSHEA, but enforcement discretion has stabilized the category in practice. The GlyNAC era has emerged in the 2020s with research from Sekhar and colleagues at Baylor College of Medicine. The glycine + NAC combination supports comprehensive glutathione synthesis (both amino acid precursors); preliminary research in older adults shows substantial benefits in mitochondrial function, insulin resistance, inflammation markers, and other healthy aging endpoints. This research is preliminary but mechanistically compelling; expanded clinical trials are underway.

1. 1960sZambon (Italy) develops N-acetylcysteine as mucolytic
2. 1963Sheffner characterizes pharmacology in Ann N Y Acad Sci
3. 1973Mitchell characterizes acetaminophen glutathione mechanism
4. 1977Prescott foundational acetaminophen overdose trial (Lancet)
5. 1988Smilkstein IV NAC protocol (NEJM)
6. 2004FDA approves IV Acetadote for acetaminophen overdose
7. 2005BRONCUS COPD trial (Decramer); IFIGENIA pulmonary fibrosis
8. 2008Berk schizophrenia and bipolar adjunctive trials; Grant pathological gambling
9. 2009Bloch trichotillomania (Arch Gen Psychiatry)
10. 2010Gray cocaine dependence trial
11. 2015Sarris OCD systematic review
12. 2020-2021FDA NAC supplement classification controversy
13. 2022FDA enforcement discretion announcement restores consumer category
14. 2020sGlyNAC aging research expands (Sekhar Baylor)

• Whether the 2020-2022 FDA regulatory controversy will fully resolve with formal rule-making or remain in enforcement discretion limbo, current status is functional but not legally definitive.
• Whether NAC will gain integration into mainstream psychiatric guidelines for OCD, schizophrenia, or other conditions where adjunctive evidence has accumulated, currently used in specialist practice but not in standard guidelines.
• Whether the GlyNAC (glycine + NAC) protocols showing aging-related benefits in preliminary research translate to broader healthy aging applications.
• Whether NAC has specific COVID-19 or post-acute COVID applications beyond the preliminary respiratory and antioxidant mechanisms.
• Whether routine high-dose NAC supplementation in healthy users provides meaningful health benefits beyond glutathione status improvement, hard endpoint evidence in healthy users remains limited.
• How best to integrate NAC with established addiction treatment given the preliminary cocaine, gambling, and other substance use disorder evidence, clinical implementation is uneven.
• Whether the cystine-glutamate antiporter mechanism has specific applications beyond addiction (compulsive behaviors, neurodegeneration) where preliminary research is emerging.
• Whether sustained-release or other NAC formulations produce clinically meaningful advantages over standard release at equivalent total doses.

Widely available globally as dietary supplement and pharmaceutical product. Legal under DSHEA in the United States, the November 2022 FDA enforcement discretion announcement effectively restored the consumer supplement category after the 2020-2022 controversy. Legal in equivalent supplement regulations in most jurisdictions. Not on WADA prohibited list. Pharmaceutical preparations: IV Acetadote (Cumberland Pharmaceuticals) FDA-approved for acetaminophen overdose; nebulized Mucomyst for mucolytic use; effervescent NAC tablets pharmaceutical in Europe. Major retail supplement brands include NOW Foods, Thorne, Pure Encapsulations, Jarrow Formulas, Designs for Health, Life Extension, and many others. Pricing has remained reasonable through the FDA controversy period. The Zambon (Italian pharmaceutical company) original NAC patent expired decades ago; generic production is widespread globally. Quality verification through USP, NSF, and Informed Sport third-party testing provides standard assurance. The Italian pharmaceutical heritage (Zambon, Esoxin, Fluimucil) continues to inform global NAC quality standards.

Status current as of July 2026. Regulatory positions change, sometimes quickly.

Class

Synthetic acetylated amino acid derivative

Mechanism

Cysteine precursor for glutathione synthesis

Standard supplementation

600-1200mg/day

Psychiatric high-dose protocols

2400mg/day

Acetaminophen overdose (IV loading)

150mg/kg

Foundational pharmaceutical development

1960s Zambon Italy

What follows is unfinished work on our side, not a finding about NAC. A short entry is not a safe entry.

• Cost and market. We have not documented what it sells for or who sells it.
• Supply chain. We have not mapped where it is made.
• Who uses it. We have not documented the user groups.
• What could change. No forward-looking summary yet.
• How it compares. We have not set it against the alternatives.
• Children and teenagers. We have not checked what is known about younger people.
• Where we land. We have not taken a position on this yet.